Blockchain Registration Transaction Record

Annovis Bio Raises $15M to Advance Alzheimer's and Parkinson's Drug

Annovis Bio (NYSE: ANVS) prices $15M public offering to fund buntanetap clinical trials for Alzheimer's and Parkinson's. Learn about the drug's mechanism and company updates.

This funding is critical for Annovis Bio to continue clinical development of buntanetap, a promising therapy targeting the root causes of Alzheimer's and Parkinson's diseases. If successful, buntanetap could become a disease-modifying treatment for millions, addressing a massive unmet need in neurodegenerative diseases that currently have limited options. Investors and patients should watch this space as Annovis progresses toward Phase 3 trials.